Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 16 (June 1), 2007: pp. 2313-2321
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.08.6900

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Dwyer, P. J.
Right arrow Articles by O'Connell, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Dwyer, P. J.
Right arrow Articles by O'Connell, M. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL ARTICLE

Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups

Peter J. O'Dwyer, S. Gail Eckhardt, Daniel G. Haller, Joel Tepper, Dennis Ahnen, Stanley Hamilton, Al B. Benson, III, Mace Rothenberg, Nicholas Petrelli, Heinz-Joseph Lenz, Robert Diasio, Raymond DuBois, Daniel Sargent, Jeff Sloan, C. Daniel Johnson, Robert L. Comis, Michael J. O'Connell

From the Coalition of Cancer Cooperative Groups; University of Pennsylvania, Abramson Cancer Center, Philadelphia; Allegheny Cancer Center, Pittsburgh, PA; University of Colorado Health Sciences Center, Denver, CO; Mayo Clinic; Mayo Clinic Comprehensive Cancer Center, Rochester, MN; University of California, San Francisco; University of Southern California Norris Cancer Center, Los Angeles, CA; Vanderbilt-Ingram Cancer Center, Nashville, TN; University of North Carolina, Chapel Hill, NC; Mayo Clinic Scottsdale, Scottsdale, AZ; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Helen F. Graham Cancer Center, Newark, DE; University of Chicago, Chicago, IL; and the Princess Margaret Hospital, Toronto, Canada

Address reprint requests to Peter J. O'Dwyer, MD, University of Pennsylvania Cancer Center, 51 N 39th St, MAB-103, Philadelphia, PA 19104; email: peter.odwyer{at}uphs.upenn.edu

Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.

The Council held its initial meeting in Philadelphia, PA, on December 13-14, 2004. A follow-up Scientific Dialogue with representatives of oncology-focused pharmaceutical companies and the patient advocacy community was held in Dana Point, CA, on April 14-15, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
E. Goekkurt, S.-E. Al-Batran, J. T. Hartmann, U. Mogck, G. Schuch, M. Kramer, E. Jaeger, C. Bokemeyer, G. Ehninger, and J. Stoehlmacher
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
J. Clin. Oncol., June 10, 2009; 27(17): 2863 - 2873.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online